Baron Funds, an investment management company, released its fourth-quarter investor letter for the “Baron Health Care Fund”. A copy of the letter can be downloaded here. The fund rose 13.10% (Institutional Shares) in the quarter, compared to a 11.92% gain for the Russell 3000 Health Care Index (benchmark) and a 2.40% gain for the Russell 3000 Index (the Index). The Fund returned 10.28% for the full year, compared to 14.56% and 17.15% gains for the indexes, respectively. Strong stock selection in biotechnol ...

Argenx SE (NASDAQ:ARGX) is one of the 10 best NASDAQ growth stocks to buy for the next 10 years. According to a report released on January 21, Emily Bodnar of H.C. Wainwright maintained a Buy rating along with the price target of $915 on Argenx SE (NASDAQ:ARGX). The firm’s price target reflects a modest 8.93% upside from the current levels. Is argenx SE (ARGX) the Best Cancer Stock to Invest in for Long-Term Gain? Additionally, on January 20, Wells Fargo reiterated its Buy rating on Argenx SE (NASDAQ:ARG ...

Core Insights - Argenx SE – ADR (NASDAQ:ARGX) is recognized as a promising healthcare stock for 2026, particularly following the FDA's acceptance of a priority review for its drug Vyvgart [1][2] Group 1: FDA Review and Drug Indication - The FDA has granted priority review status for a supplemental biologics license application aimed at expanding Vyvgart's use for treating adults with acetylcholine receptor antibody-seronegative generalized myasthenia gravis (gMG) [2] - If the application is successful, it will broaden the patient population eligible for Vyvgart, potentially increasing its market reach [2] Group 2: Sales Momentum and Market Sentiment - William Blair has reiterated an Outperform rating on Argenx, citing strong sales momentum in the Vyvgart franchise, with sales exceeding expectations [3] - The positive sales trend is anticipated to continue through 2026 across indications in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) [3] Group 3: Company Overview - Argenx SE is a Netherlands-based global biotechnology company focused on developing, manufacturing, and commercializing antibody-based therapies for severe autoimmune diseases and cancers [4]

Core Viewpoint - Biotech stocks are outperforming in the current stock market rally, with key players like Amgen, Gilead Sciences, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, and Argenx trading in or near buy zones as the fourth-quarter earnings season approaches [1] Group 1: Company Performance - Amgen (AMGN) is highlighted as a leading Dow Jones index component and industry giant, indicating strong market positioning [1] - Gilead Sciences (GILD) is noted for generating improved relative strength, suggesting positive market sentiment and potential for growth [1] - Regeneron Pharmaceuticals (REGN) is experiencing stock volatility but shows potential for business development deals following a solid fourth-quarter report [1] Group 2: Market Trends - The fourth-quarter earnings season is expected to reveal stock market leadership dynamics, indicating a critical period for investors [1] - The overall stock market is responding positively to recent developments, with the Nasdaq, Dow, and S&P 500 finding buyers at key levels [1] - Stocks like Gilead Sciences are showing renewed technical strength, which may attract further investment [1]

Group 1 - Argenx SE (NASDAQ:ARGX) is recognized as one of the top high-growth European stocks, with an Outperform rating maintained by William Blair due to strong sales growth in its Vyvgart brand [1] - Vyvgart sales are exceeding expectations and are expected to maintain solid momentum through 2026 for applications in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) [1] - The FDA has agreed to prioritize a supplemental biologics licensing application for Vyvgart, which aims to expand its use in treating adults with acetylcholine receptor antibody-seronegative generalized myasthenia gravis (gMG) [3] Group 2 - Argenx is developing treatments for severe autoimmune diseases and operates in four segments: the United States, Japan, EMEA, and China [4] - The company has other clinical products in development, such as empasiprubart for multifocal motor neuropathy (MMN), with pivotal data expected in the fourth quarter of 2026 [2]

Argenx SE (NASDAQ:ARGX) is one of the 11 Best Stocks to Buy for Investment. On January 20, TheFly reported that Wells Fargo increased the price target on Argenx SE (NASDAQ:ARGX) from $1,264 to $1,317, keeping an Overweight rating on the shares. Wells Fargo Analysts Sees Potential in Argenx SE's Vyvgart, Increases PT To $1,317 Pixabay/Public Domain Derek Archila from Wells Fargo raised the price target on ARGX following its strong outlook on Argenx’s Vyvgart, according to TheFly. Archila has raised the ...

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are highlighted, indicating a looming crisis in power supply as AI continues to grow [2][3] Investment Opportunity - A specific company is noted as a potential investment opportunity, possessing critical energy infrastructure assets that are essential for supporting the increasing energy needs of AI data centers [3][7] - This company is described as a "toll booth" operator in the AI energy boom, benefiting from the surge in demand for electricity driven by AI advancements [4][5] Market Position - The company is positioned at the forefront of America's energy strategy, owning significant nuclear energy infrastructure and being capable of executing large-scale projects across various energy sectors [7][8] - It is noted that this company is debt-free and has a substantial cash reserve, equating to nearly one-third of its market capitalization, which provides a strong financial foundation [8][10] Competitive Advantage - The company also holds a significant equity stake in another AI-related venture, offering investors indirect exposure to multiple growth opportunities in the AI sector without the associated high premiums [9][10] - The stock is described as undervalued, trading at less than 7 times earnings, which presents a compelling investment case compared to other firms in the energy and utility sectors [10][11] Industry Trends - The article discusses the broader trends of onshoring and tariffs under the Trump administration, which are expected to drive growth in U.S. LNG exports and benefit the company [6][14] - The influx of talent into the AI sector is noted, ensuring continuous innovation and advancements, which further supports the investment thesis in AI-related companies [12][13]

We came across a bullish thesis on argenx SE on Lux Opes Research’s Substack. In this article, we will summarize the bulls’ thesis on ARGX. argenx SE's share was trading at $833.16 as of January 26th. ARGX’s trailing and forward P/E were 35.64 and 27.93 respectively according to Yahoo Finance. Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress Copyright: nexusplexus / 123RF Stock Photo argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of ...

ClearBridge Investments, an investment management company, released its “ClearBridge Mid Cap Strategy” Q4 2025 investor letter. A copy of the letter can be downloaded here. During the quarter, the ClearBridge Mid Cap Strategy reported underperformance versus the Russell Midcap Index, which returned 0.16% during the period, as narrow market leadership and sentiment-driven trading weighed on results. Weakness in information technology and real estate holdings pressured returns, while gains in select consumer ...